危重症患者艾沙康唑血药浓度低于其他人群:可能需要治疗药物监测
该回顾性分析纳入2019年1月1日至2022年10月26日接受标准剂量艾沙康唑治疗的患者,比较ICU与非ICU患者的血药浓度。ICU患者平均血药浓度显著低于非ICU患者(2.02±1.22 vs 4.15±2.31 mg/L,P<0.001),亚治疗浓度比例更高。作者认为ICU患者应进行艾沙康唑疗效相关的治疗药物监测。
要点
- ICU患者艾沙康唑平均血药浓度2.02±1.22 mg/L,显著低于非ICU患者的4.15±2.31 mg/L(P<0.001)。
- ICU患者全部测定值<2 mg/L的比例为33.3%,非ICU患者为7.7%;全部<1 mg/L的比例分别为12.1%和0%。
- 作者认为ICU患者应进行艾沙康唑疗效相关的治疗药物监测。
核心结论
- ICU患者艾沙康唑血药浓度显著低于非ICU人群。
- 作者认为ICU患者应进行艾沙康唑疗效相关的治疗药物监测。
研究设计与样本
- 回顾性分析2019年1月1日至2022年10月26日接受标准剂量艾沙康唑治疗的全部患者数据。
- 共纳入72例患者(中位年龄65岁)和188次治疗药物监测测定(每例患者平均样本数2.6±1.7)。
- 33例(45.8%)为ICU患者(其中3例合并血液系统疾病),39例(54.2%)为非ICU患者(其中31例有血液系统疾病)。
主要发现
- 全部患者艾沙康唑平均血药浓度为3.33±2.26 mg/L。
- ICU患者平均血药浓度2.02±1.22 mg/L,显著低于非ICU患者的4.15±2.31 mg/L(P<0.001)。
- ICU患者全部测定值<2 mg/L的比例为33.3%,非ICU患者为7.7%;全部测定值<1 mg/L的比例分别为12.1%和0%,ICU患者亚治疗浓度比例显著更高。
- 较低艾沙康唑水平的预测因素为入住ICU、BMI>25 kg/m2、胆红素>1.2 mg/dL和无血液系统疾病。
临床怎么用
- 作者认为ICU患者应进行艾沙康唑疗效相关的治疗药物监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isavuconazole is first-line treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) is deemed not necessary, since most patients reached therapeutic levels (>1 mg/L) in large studies. Low levels were reported in some critically ill patients admitted to the ICU. The aim was to compare isavuconazole levels between critically ill and non-critically ill patients. MATERIALS AND METHODS: Retrospective analysis of data from all patients treated with standard-dose isavuconazole between 1 January 2019 and 26 October 2022 was performed. The following data were collected: TDM results from the first 30 days of therapy; ward of admission; demographic and clinical characteristics; continuous renal replacement therapy; extracorporeal membrane oxygenation; and co-administered drugs. RESULTS: Seventy-two patients (median age 65 years) and 188 TDM measurements (mean number of samples per patient 2.6 ± 1.7) were included; 33 (45.8%) were ICU patients (3 also had haematological disorders); 39 (54.2%) were non-ICU patients, of whom 31 had haematological disorders. In all patients, the mean isavuconazole blood level was 3.33 ± 2.26 mg/L. Significantly lower levels were observed in the ICU versus the non-ICU population: mean 2.02 ± 1.22 versus 4.15 ± 2.31 mg/L (P < 0.001). Significantly higher rates of subtherapeutic levels were observed in ICU patients compared with the non-ICU population: all determinations <2 mg/L in 33.3% versus 7.7%, and all determinations <1 mg/L in 12.1% versus 0%, respectively. Predictors of lower isavuconazole levels were admission to the ICU, BMI > 25 kg/m2, bilirubin > 1.2 mg/dL and the absence of haematological disorder. CONCLUSIONS: ICU patients had significantly lower isavuconazole blood levels compared to non-ICU population. The TDM of isavuconazole for efficacy should be performed in ICU.
引用
- Mikulska M, Melchio M, Signori A, et al. Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring. J Antimicrob Chemother. 2024. PMID: 38366368. doi:10.1093/jac/dkae037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。